Global Osteoporosis Drugs Market 2014-2018

TechNavio's analysts forecast the Global Osteoporosis Drugs market to grow at a CAGR of 3.98 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The Global Osteoporosis Drugs market has also been witnessing the increasing awareness of bone health education. However, the multiple patent expiries could pose a challenge to the growth of this market.
TechNavio's report, the Global Osteoporosis Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Osteoporosis Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this space are Amgen Inc., Eli Lilly & Co., Merck & Co. Inc., and Novartis AG.
Other vendors mentioned in the report are Abiogen Pharma SpA, F. Hoffmann La Roche Ltd., GlaxoSmithKline plc, Ligand Pharmaceuticals Inc., NPS Pharma Inc., and Pfizer Inc.
Key questions answered in this report:
What will the market size be in 2016/2018 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Osteoporosis Drugs Market in the US
06.3.1 Market Size and Forecast
06.4 Osteoporosis Drugs Market in Europe
06.4.1 Market Size and Forecast
06.5 Five Forces Analysis
07. Market Segmentation by Drug Class
08. Geographical Segmentation
08.1 Osteoporosis Drugs Market in the Americas
08.2 Osteoporosis Drugs Market in the EMEA Region
08.3 Osteoporosis Drugs Market in the APAC Region
09. Buying Criteria
10. Rate of Incidence and Prevalence
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.1.2 Mergers and Acquisitions
17.2 Market Share Analysis 2013
17.3 Other Prominent Vendors
18. Key Vendor Analysis
18.1 Amgen Inc.
18.1.1 Business Overview
18.1.2 Key Information
18.1.3 SWOT Analysis
18.2 Eli Lilly & Co.
18.2.1 Business Overview
18.2.2 Key Information
18.2.3 SWOT Analysis
18.3 Merck & Co. Inc.
18.3.1 Business Overview
18.3.2 Business Segmentation
18.3.3 Key Information
18.3.4 SWOT Analysis
18.4 Novartis AG
18.4.1 Business Overview
18.4.2 Business Segmentation
18.4.3 Key Information
18.4.4 SWOT Analysis
19. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Osteoporosis Drugs Market 2013-2018 (US$ billion)
Exhibit 3: Osteoporosis Drugs Market in the US 2013-2018 (US$ billion)
Exhibit 4: Osteoporosis Drugs Market in Europe 2013-2018 (US$ billion)
Exhibit 5: Global Osteoporosis Drugs Market Segmentation by Drug Class
Exhibit 6: Global Osteoporosis Drugs Market by Geographical Segmentation 2013
Exhibit 7: Osteoporosis Drugs Market in the Americas 2013-2018 (US$ billion)
Exhibit 8: Osteoporosis Drugs Market in the EMEA Region 2013-2018 (US$ billion)
Exhibit 9: Osteoporosis Drugs Market in the APAC Region 2013-2018 (US$ billion)
Exhibit 10: Global Osteoporosis Drugs Market by Geographical Segmentation (percentage)
Exhibit 11: Comparison of YOY Growth Rate by Region for Global Osteoporosis Market 2013-2018
Exhibit 12: Business Segmentation of Merck & Co. Inc.
Exhibit 13: Business Segmentation of Novartis AG